美国血液学会——第51届年会暨学术会议。第二部分
American Society of Hematology--51st annual meeting & exposition. Part 2.
作者信息
Shumoogam Jaya, Beecher Natasher
机构信息
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
出版信息
IDrugs. 2010 Feb;13(2):60-2.
PMID:20127550
Abstract
The 51st Annual Meeting & Exposition of the American Society of Hematology, held in New Orleans, included topics covering new therapeutic developments in the field of hematology. This conference report highlights selected presentations on combination regimens for the treatment of multiple myeloma, selected kinase inhibitors and a recombinant HOXB4 protein. Investigational drugs discussed include SB-1518 (S*Bio Pte Ltd) and PF-2341066 (Pfizer Inc).
摘要
在美国新奥尔良举行的第51届美国血液学会年会暨展览会涵盖了血液学领域新治疗进展的诸多主题。本会议报告重点介绍了关于多发性骨髓瘤联合治疗方案、特定激酶抑制剂及重组HOXB4蛋白的部分演讲内容。所讨论的研究性药物包括SB - 1518（S*Bio私人有限公司）和PF - 2341066（辉瑞公司）。
相似文献
1
American Society of Hematology--51st annual meeting & exposition. Part 2.
IDrugs. 2010 Feb;13(2):60-2.
2
American Society of Hematology--51st annual meeting & exposition. Part 1.
IDrugs. 2010 Feb;13(2):57-9.
3
4
Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
IDrugs. 2009 Dec;12(12):750-3.
5
6
Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.
IDrugs. 2009 Dec;12(12):731-3.
7
8
Clinical trials in CNS--SMi's eighth annual conference.
IDrugs. 2010 Feb;13(2):66-9.
9
American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.
IDrugs. 2010 Sep;13(9):598-600.
10
HDAC Inhibitors--CHI's Third Annual Conference.
IDrugs. 2010 Jan;13(1):13-5.
Zotero 插件